Free Trial

Aclaris Therapeutics (ACRS) Stock Forecast & Price Target

$1.04
+0.04 (+3.47%)
(As of 12:51 PM ET)

Aclaris Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 7 Analyst Ratings

Consensus Price Target

$22.25
2,029.19% Upside
High Forecast$38.00
Average Forecast$22.25
Low Forecast$9.00
TypeCurrent Forecast
5/31/23 to 5/30/24
1 Month Ago
5/1/23 to 4/30/24
3 Months Ago
3/2/23 to 3/1/24
1 Year Ago
5/31/22 to 5/31/23
Consensus Rating
Hold
Hold
Hold
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
6 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$22.25$22.25$23.17$32.00
Forecasted Upside2,029.19% Upside302.86% Upside274.37% Upside212.32% Upside
Get Aclaris Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.

ACRS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ACRS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Aclaris Therapeutics Stock vs. The Competition

TypeAclaris TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.14
2.70
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside2,102.97% Upside731.03% Upside12.20% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/22/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Selvaraju
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
1/12/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
1/11/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Neutral
11/13/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
11/13/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
11/13/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Lugo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
10/3/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$22.00+238.98%
3/7/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$25.00 ➝ $21.00+183.40%
11/8/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:12 PM ET.

ACRS Frequently Asked Questions

What is Aclaris Therapeutics's stock forecast and purchase recommendation?

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Aclaris Therapeutics is $22.25, with a high forecast of $38.00 and a low forecast of $9.00. The consensus rating for Aclaris Therapeutics stock is Hold based on the current 6 hold ratings and 1 buy rating for ACRS. Learn more on ACRS's analyst rating history.

Do Wall Street analysts like Aclaris Therapeutics more than its competitors?

Analysts like Aclaris Therapeutics less than other "medical" companies. The consensus rating for Aclaris Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ACRS compares to other companies.

Does Aclaris Therapeutics's stock price have much upside?

According to analysts, Aclaris Therapeutics's stock has a predicted upside of 302.86% based on their 12-month stock forecasts.


Stock Forecasts and Research Tools

This page (NASDAQ:ACRS) was last updated on 5/30/2024 by MarketBeat.com Staff

From Our Partners